Floatz logo

n17350

Carcinoma, Squamous Cell

Onchilles Pharma IncPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Carcinoma, Squamous Cell cohort.

Asset / SponsorPhaseRating
Carboplatin
Neonc Technologies, Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Oxford
Phase 3BB
Docetaxel
Hummingbird Bioscience
Phase 2BB
Eloxatin
University of Oxford
Phase 3BB
Fibrin Sealant
Oxford University Hospitals NHS Trust
Phase 4BB

View all 50 →

Same molecule, other indications

n17350 is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
skin squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
head and neck neoplasmDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →